The Rise of Bispecific Combination Trials

The number of bispecific combination trials has seen substantial growth in recent years and 2023 has been the biggest year to date, with 211 combination trials initiated, representing 65% of all trials! Gain insights into the driving factors behind the surge, particularly the role of small molecule therapies, which account for 475 trials and exhibit synergy with bispecific immunotherapy.

Dive into invaluable trial phase data, demonstrating the potential of combination methods and their increased likelihood of progressing to late-stage clinical development compared to monotherapies. Get ahead in the realm of therapeutic innovation by accessing the latest insights into combined strategies.